Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Heterotaxy, Polysplenia : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Asplenia




Patient Education
Click here for patient education.



Author: Kevin M Shannon, MD, Associate Professor, Division of Pediatric Cardiology, Director of Pediatric Electrophysiology Program, UCLA School of Medicine; Consulting Staff, Pediatric Cardiology Clinic, Olive View-UCLA Medical Center

Kevin Shannon is a member of the following medical societies: American Academy of Pediatrics

Editors: Charles Berul, MD, Associate Professor of Pediatrics, Harvard Medical School; Senior Associate, Department of Cardiology, Children's Hospital of Boston; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; Julian M Stewart, MD, PhD, Director of Center for Pediatric Hypotension, Professor, Departments of Pediatrics and Physiology, Division of Pediatric Cardiology, Westchester Medical Center and New York Medical College; Gilbert Herzberg, MD, Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College; Stuart Berger, MD, Professor of Pediatrics, Division of Cardiology, Medical College of Wisconsin; Chief of Pediatric Cardiology, Medical Director of Pediatric Heart Transplant Program, Medical Director of The Heart Center, Children's Hospital of Wisconsin

Author and Editor Disclosure

Synonyms and related keywords: polysplenia, heterotaxy syndrome, left atrial isomerism, polysplenia syndrome, cyanotic congenital heart disease, biliary atresia, intestinal malrotation, functional asplenia, jaundice

Background

Polysplenia is a heterogeneous disease that primarily affects the asymmetric organs, including the heart, lungs and bronchi, liver, intestines, and spleen. Primary manifestations of this disease include cyanotic congenital heart disease, biliary atresia, intestinal malrotation, and functional asplenia.

Pathophysiology

The exact cause of polysplenia has not been defined, but it appears to be multifactorial, with some familial predisposition. Embryologically, it results from failure of development of right-left asymmetry. Several candidate genes have been suggested as causing failure of lateralization, and genetically engineered animal models have similar findings.

Frequency

United States

Polysplenia accounts for approximately 0.4% of cases of congenital heart disease and occurs in an estimated 4 per 1 million live births.

Mortality/Morbidity

Approximately 80% of patients with polysplenia have congenital heart disease. Mortality can result from congenital heart disease, biliary atresia, intestinal malrotation, or sepsis. In one large retrospective review from Canada, the 1-year mortality rate was 32% and the 15-year mortality rate was 49%.

Race

No predisposition based on race has been reported.

Sex

No predisposition based on sex has been reported. However, polysplenia has been reported to sometimes be transmitted in an X-linked recessive fashion.

Age

Polysplenia is present from birth, although clinical detection may be delayed, depending on the severity of congenital heart disease and gastrointestinal abnormalities.



History

Patients most commonly present with symptoms of congenital heart disease in the newborn period. Jaundice caused by biliary tract abnormalities is the second most common neonatal presentation. A small percentage of patients present with abdominal symptoms or are diagnosed because of an incidental finding of situs abnormalities (eg, dextrocardia, intestinal malrotation).

Physical

Cyanosis, congestive heart failure, and persistent jaundice are the most common physical findings in patients who present in the newborn period. For patients who present later, isolated dextrocardia (with right-sided heart sounds) and a transverse liver may be the only abnormalities observed on physical examination.

Causes

The cause(s) of polysplenia syndrome are unknown but are believed to be multifactorial. The incidence of polysplenia has not been studied extensively, but it appears to be rare, comprising less than 1% of congenital heart defects. In a 26-year retrospective study at the Hospital for Sick Children in Toronto Canada, only 91 cases were identified. Familial cases have been reported, along with single-family reports of gene linkage. However, no reproducible patterns of inheritance have been identified, nor has a gene for this disease been identified. Different forms of heterotaxy, including asplenia and polysplenia, may occur within the same family. Animal studies have implicated several genes as possible causes of polysplenia syndrome. Retinoic acid has been implicated as a cause of polysplenia syndrome in mouse embryos.

Polysplenia syndrome is commonly associated with other defects of lateralization, including intestinal malrotation, transverse liver, and genitourinary abnormalities.



Asplenia

Other Problems to be Considered

Situs inversus (Kartagener syndrome)



Lab Studies

  • Useful laboratory studies include a CBC count with peripheral smear to look for Howell-Jolly bodies and evidence of impaired splenic function.
  • Arterial blood gas measurements to assess for cyanotic heart disease may also be indicated.

Imaging Studies

  • Complete echocardiography is indicated in any patient with suspected polysplenia to evaluate for associated congenital heart disease.
  • Routine chest radiography is indicated to assess the cardiac size and location, the bronchial anatomy (usually bilateral left bronchi are present), and abdominal situs.
  • In addition, an upper GI study has been proposed as a routine study in patients with polysplenia because of the high incidence of intestinal malrotation and the risk of volvulus.
  • Liver-spleen scanning and abdominal ultrasonography are useful for determination of organ size, location, and function. Liver-spleen scanning is indicated to confirm the presence of functional splenic tissue. The presence of multiple small spleens is common in polysplenia.

Other Tests

  • A 12-lead ECG is often helpful because an abnormal P wave axis is common in patients with polysplenia, and conduction system abnormalities (eg, complete heart block, sick sinus syndrome, supraventricular tachycardia [SVT]) are common.
  • Additional studies of cardiac conduction, particularly 24-hour Holter monitoring, may be indicated by the clinical setting.
  • Additional studies of the biliary tract may be indicated in patients with prolonged jaundice or other signs of biliary atresia.

Procedures

  • Cardiac catheterization
    • Patients presenting with cardiac malformations often require cardiac catheterization on one or more occasions. In the newborn period, cardiac catheterization may be indicated to assess systemic and pulmonary venous connections. Later, cardiac catheterization may be indicated to determine individual candidacy for surgical intervention.
    • Cardiac catheterization can often be carried out with a venous approach, accessing the left heart through an atrial septal defect (ASD) or patent foramen ovale (PFO). This is particularly important in the newborn period when small vessel size can increase the risk of vascular complication. Although no data exist, the authors' experience with catheterization via the umbilical vein has suggested that many patients with heterotaxy syndrome have an abnormal ductus venosus, making cannulation difficult. However, umbilical venous cannulation is possible and can preserve femoral access for future interventions.
    • The goals of diagnostic catheterization are usually to provide hemodynamic and physiologic data to assist with medical and surgical decision-making. Anatomic information is rarely required in the era of modern echocardiography. Echocardiography can be limited in assessing pulmonary venous return, branch pulmonary artery anatomy, and aortopulmonary collaterals, so these issues occasionally require clarification via cardiac catheterization.
    • Postcatheterization precautions include hemorrhage, vascular disruption after balloon dilation, pain, nausea and vomiting, and arterial or venous obstruction from thrombosis or spasm.
    • Possible complications include rupture of blood vessel, tachyarrhythmias, bradyarrhythmias, and vascular occlusion.



Medical Care

Medical therapy is typically directed at the findings of the initial evaluation. Anticongestive medication is often required in patients with significant left-to-right shunts. Patients with functional asplenia require antibiotic prophylaxis and the pneumococcal vaccine.

Surgical Care

Surgical care is also directed at the findings of the initial evaluation. Patients with significant cardiac disease may require staged palliation or definitive repair, whereas patients with biliary atresia may require initial palliative surgery followed by liver transplantation.

Consultations

Patients with polysplenia syndrome can present with a variety of noncardiac problems, primarily gastrointestinal tract abnormalities but also genitourinary abnormalities. Patients presenting with evidence of intestinal obstruction, volvulus, or both should have a consultation with a general surgeon and appropriate imaging studies to rule out malrotations. Consultation with an infectious disease specialist may also be warranted if bacterial infection is suspected because patients with polysplenia associated with abnormal splenic function are more susceptible to certain bacterial pathogens.



Cardiomyopathy with significant left-to-right shunts may require treatment for congestive heart failure. According to American Heart Association guidelines, pneumococcal vaccine and antibiotics for SBE prophylaxis are necessary in patients with functional asplenia. Antibiotic prophylaxis is administered to patients before performing procedures that may cause bacteremia. For more information, see Antibiotic Prophylactic Regimens for Endocarditis.

Drug Category: Diuretic agents

These agents promote excretion of water and electrolytes by the kidneys. They are used to treat heart failure or hepatic, renal, or pulmonary disease when sodium and water retention has resulted in edema or ascites. The agents may be used as monotherapy or combination therapy to treat hypertension.

Drug NameFurosemide (Lasix)
DescriptionUsed to treat edema. Increases excretion of water by interfering with chloride-binding cotransport system which, in turn, inhibits sodium and chloride reabsorption in ascending loop of Henle and distal renal tubule. Dose must be individualized to patient. Depending on response, administer at 20- to 40-mg increments, no sooner than 6-8 h after the previous dose, until desired diuresis occurs. When treating infants, titrate with 1-mg/kg/dose increments until a satisfactory effect is achieved.
Adult Dose20-80 mg/d PO/IV/IM; may titrate up to 600 mg/d for severe edematous states
Pediatric Dose3-6 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity; hepatic coma; anuria; state of severe electrolyte depletion
InteractionsMetformin decreases furosemide concentrations; furosemide interferes with hypoglycemic effect of antidiabetic agents and antagonizes muscle-relaxing effect of tubocurarine; auditory toxicity appears to be increased with coadministration of aminoglycosides and furosemide; hearing loss of varying degrees may occur; anticoagulant activity of warfarin may be enhanced when taken concurrently with this medication; increased plasma lithium levels and toxicity are possible when taken concurrently with this medication
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsPerform frequent serum electrolyte, carbon dioxide, glucose, creatinine, uric acid, calcium, and BUN determinations during first few months of therapy and periodically thereafter

Drug NameSpironolactone (Aldactone)
DescriptionFor management of edema resulting from excessive aldosterone excretion. Competes with aldosterone for receptor sites in distal renal tubules, increasing water excretion while retaining potassium and hydrogen ions.
Adult Dose25-200 mg/d PO divided q12-24h
Pediatric Dose1-3 mg/kg/d PO divided tid
ContraindicationsDocumented hypersensitivity; anuria; renal failure; hyperkalemia
InteractionsMay decrease effect of anticoagulants; potassium and potassium-sparing diuretics may increase toxicity of spironolactone
PregnancyD - Unsafe in pregnancy
PrecautionsCaution in renal and hepatic impairment

Drug Category: Inotropic agents

Positive inotropes increase the force of contraction of the myocardium and are used to treat acute and chronic congestive heart failure. Some may also increase or decrease the heart rate (ie, positive or negative chronotropic agents), provide vasodilatation, or improve myocardial relaxation. These additional properties influence the choice of drug for specific circumstances. Those used predominantly for their inotropic effects include cardiac glycosides and phosphodiesterase inhibitors.

Drug NameDigoxin (Lanoxin)
DescriptionUsed to treat congestive heart failure. Cardiac glycoside with direct inotropic effects, in addition to indirect effects on the cardiovascular system. Acts directly on cardiac muscle, increasing myocardial systolic contractions. Its indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.
Adult Dose0.125-0.375 mg PO qd
Pediatric Dose10 mcg/kg/d PO divided bid
ContraindicationsDocumented hypersensitivity; beriberi heart disease; idiopathic hypertrophic subaortic stenosis; constrictive pericarditis; carotid sinus syndrome
InteractionsIV calcium may produce arrhythmias in digitalized patients
Medications that may increase digoxin levels include alprazolam, benzodiazepines, bepridil, captopril, cyclosporine, propafenone, propantheline, quinidine, diltiazem, aminoglycosides, PO amiodarone, anticholinergics, diphenoxylate, erythromycin, felodipine, flecainide, hydroxychloroquine, itraconazole, nifedipine, omeprazole, quinine, ibuprofen, indomethacin, esmolol, tetracycline, tolbutamide, and verapamil
Medications that may decrease serum digoxin levels include aminoglutethimide, antihistamines, cholestyramine, neomycin, penicillamine, aminoglycosides, PO colestipol, hydantoins, hypoglycemic agents, antineoplastic treatment combinations (including carmustine, bleomycin, methotrexate, cytarabine, doxorubicin, cyclophosphamide, vincristine, procarbazine), aluminum or magnesium antacids, rifampin, sucralfate, sulfasalazine, barbiturates, kaolin/pectin, and aminosalicylic acid
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsHypokalemia may reduce positive inotropic effect of digitalis; hypercalcemia predisposes patient to digitalis toxicity, and hypocalcemia can make digoxin ineffective until serum calcium levels are within the reference range; magnesium replacement therapy must be instituted in patients with hypomagnesemia to prevent digitalis toxicity; patients with incomplete atrioventricular (AV) block may progress to complete block when treated with digoxin; exercise caution in hypothyroidism, hypoxia, and acute myocarditis; adjust dose in renal impairment; highly toxic (overdoses can be fatal)

Drug Category: Angiotensin-converting enzyme (ACE) inhibitors

ACE inhibitors are beneficial in all stages of congestive heart failure. Pharmacologic effects result in a decrease in systemic vascular resistance, reducing blood pressure, preload, and afterload. Dyspnea and exercise tolerance are improved. Unlike diuretics, studies demonstrate improvement of survival and reduced progression of mild or moderate heart failure to more severe stages. ACE inhibitors benefit asymptomatic left ventricular dysfunction.

Drug NameEnalapril (Vasotec)
DescriptionUsed to treat congestive heart failure. Competitive inhibitor of ACE. Reduces angiotensin II levels, decreasing aldosterone secretion.
Adult Dose2.5-5 mg/d PO, increase prn; dosing range is 10-40 mg/d PO in 1-2 divided doses
1.25 mg/dose IV over 5 min q6h
Pediatric Dose0.1 mg/kg/d PO initially; may gradually titrate upward; not to exceed 0.5 mg/kg/d PO divided bid
ContraindicationsDocumented hypersensitivity
InteractionsNSAIDs may reduce hypotensive effects of enalapril; ACE inhibitors may increase digoxin, lithium, and allopurinol levels; rifampin decreases enalapril levels; probenecid may increase enalapril levels; hypotensive effects of ACE inhibitors may be enhanced when coadministered with diuretics
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCategory D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe congestive heart failure

Drug Category: Vaccines

Active immunization increases resistance to infection. Vaccines consist of microorganisms or cellular components that act as antigens. Administration of the vaccine stimulates the production of antibodies with specific protective properties.

Drug NamePneumococcal vaccine (Pneumovax-23, Pnu-Imune 23)
DescriptionPolyvalent vaccine used for prophylaxis against infection from Streptococcus pneumoniae. Used in populations at increase risk of pneumococcal pneumonia (ie, age >55 y, chronic infection, asplenia, immunocompromise).
Adult Dose0.5 mL IM/SC once
Pediatric Dose<2 years: Contraindicated (antibody response is poor in this age group)
>2 years: 0.5 mL IM/SC; repeat dose after 3-5 y for high-risk children (eg, functional or anatomic asplenia, conditions associated with rapid antibody decline after initial vaccination)
ContraindicationsDocumented hypersensitivity; hypersensitivity to any component or thimerosal; severe or even moderate febrile illness; age <2 y; thrombocytopenia or any coagulation disorder that would contraindicate IM injection unless potential benefit clearly outweighs risk of administration
InteractionsImmunosuppressive agents (eg, large amounts of corticosteroids, antimetabolites, alkylating agents, cytotoxic agents) may reduce effectiveness; therapy with immunoglobulin preparations is likely to block the active immunity induced with pneumococcal vaccination, withhold for 3 mo after discontinuation of immunoglobulin therapy
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsMay cause relapse in patients with stable idiopathic thrombocytopenia purpura; adverse effects include arthralgia, fever, urticaria, and Guillain-Barré syndrome (rarely)

Drug Category: Antibiotics, prophylactic

Antibiotic prophylaxis is administered to patients before performing procedures that may cause bacteremia.

Drug NameAmoxicillin (Amoxil, Trimox)
DescriptionInterferes with synthesis of cell wall mucopeptides during active multiplication, resulting in bactericidal activity against susceptible bacteria. Used as prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure; alternatively, 3 g PO 1 h before procedure, followed by 1.5 g PO 6 h after initial dose
Pediatric Dose50 mg/kg PO 1 h before procedure; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsReduces efficacy of PO contraceptives
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment

Drug NameAmpicillin (Marcillin, Omnipen)
DescriptionFor prophylaxis in patients undergoing dental, PO, or respiratory tract procedures. Coadministered with gentamicin for prophylaxis in GI or genitourinary procedures.
Adult Dose2 g IV/IM 30 min before procedure
High-risk patients: 2 g ampicillin IV/IM plus gentamicin 1.5 mg/kg IV 30 min before procedure, followed 6 h later by 1 g ampicillin IV/IM or 1 g amoxicillin PO
Pediatric Dose50 mg/kg IV/IM 30 min before procedure; not to exceed 2 g/dose
High-risk patients: 50 mg/kg IV/IM ampicillin plus gentamicin 1.5 mg/kg IV 30 min before procedure, followed 6 h later by ampicillin 25 mg/kg IV/IM or amoxicillin 25 mg/kg PO
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction

Drug NameClindamycin (Cleocin)
DescriptionUsed in penicillin-allergic patients undergoing dental, PO, or respiratory tract procedures. Useful for treatment against streptococcal and most staphylococcal infections.
Adult Dose600 mg PO/IV 1 h before procedure and
150 mg PO/IV 6 h after first dose
Pediatric Dose20 mg/kg PO 1 h or 20 mg/kg IV 30 min before procedure; not to exceed 600 mg/dose
ContraindicationsDocumented hypersensitivity; regional enteritis; ulcerative colitis; hepatic impairment; antibiotic-associated colitis
InteractionsIncreases duration of neuromuscular blockade induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis

Drug NameGentamicin (Garamycin)
DescriptionAminoglycoside antibiotic for gram-negative coverage. Used in combination with an agent against gram-positive organisms and one that covers anaerobes.
Used in conjunction with ampicillin or vancomycin for prophylaxis in GI or genitourinary procedures.
Adult Dose1.5 mg/kg IV; not to exceed 120 mg/dose; administer with ampicillin 2 g IV 30 min before procedure
Pediatric Dose1.5 mg/kg IV; not to exceed 120 mg/dose; administer 30 min before procedure with ampicillin 50 mg/kg IV; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity; non–dialysis-dependent renal insufficiency
InteractionsCoadministration with other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; because aminoglycosides enhance effects of neuromuscular blocking agents, prolonged respiratory depression may occur; coadministration with loop diuretics may increase auditory toxicity of aminoglycosides; possible irreversible hearing loss of varying degrees may occur (monitor regularly)
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsNarrow therapeutic index (not intended for long-term therapy); caution in renal failure (patient not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment

Drug NameVancomycin (Vancocin)
DescriptionPotent antibiotic directed against gram-positive organisms and active against Enterococcus species. Useful in the treatment of septicemia and skin structure infections. Indicated for patients who cannot receive or have not responded to penicillins and cephalosporins or have infections with resistant staphylococci.
Use CrCl to adjust dose in renal impairment. Used in conjunction with gentamicin for prophylaxis in penicillin-allergic patients undergoing GI or genitourinary procedures.
Adult DoseDental, PO, or upper respiratory tract surgery: 1 g IV, infused over 1 h, 1 h before procedure
GI/GU procedures: 1 g IV plus gentamicin 1.5 mg/kg IV, infused over 1 h, 1 h before surgery
Pediatric DoseDental, PO, or upper respiratory tract surgery: 20 mg/kg IV, infused over 1 h, 1 h before procedure
ContraindicationsDocumented hypersensitivity
InteractionsErythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in renal failure or neutropenia; red man syndrome caused by too rapid IV infusion (dose administered over a few min) but rarely happens when dose is administered IV over 2 h or as PO/IP administration; red man syndrome is not an allergic reaction

Drug NameCefazolin (Ancef)
DescriptionFirst-generation semisynthetic cephalosporin that arrests bacterial cell wall synthesis, inhibiting bacterial growth. Primarily active against skin flora, including Staphylococcus aureus.
Adult Dose1 g IV/IM within 30 min before procedure
Pediatric Dose25 mg/kg IV/IM within 30 min before procedure; not to exceed 1 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsProbenecid prolongs effect; coadministration with aminoglycosides may increase renal toxicity; may yield false-positive urine dipstick test results for glucose
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameCephalexin (Keflex)
DescriptionFirst-generation cephalosporin that arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora and used for skin infections or prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure
Pediatric Dose50 mg/kg PO 1 h before procedure; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with aminoglycosides increases nephrotoxic potential
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment

Drug NameCefadroxil (Duricef)
DescriptionFirst-generation cephalosporin arrests bacterial growth by inhibiting bacterial cell wall synthesis. Bactericidal activity against rapidly growing organisms. Primary activity against skin flora and used for skin infections or prophylaxis in minor procedures.
Adult Dose2 g PO 1 h before procedure
Pediatric Dose50 mg/kg PO 1 h before procedure; not to exceed 2 g/dose
ContraindicationsDocumented hypersensitivity
InteractionsCoadministration with furosemide or aminoglycosides may increase nephrotoxicity; probenecid prolongs effects
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsAdjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy

Drug NameAzithromycin (Zithromax)
DescriptionInhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Adult Dose500 mg PO 1 h before procedure
Pediatric Dose15 mg/kg PO 1 h before procedure; not to exceed 500 mg/dose
ContraindicationsDocumented hypersensitivity; hepatic impairment; administration with pimozide
InteractionsMay increase toxicity of theophylline, warfarin, and digoxin; effects are reduced with coadministration of aluminum and/or magnesium antacids; nephrotoxicity and neurotoxicity may occur when coadministered with cyclosporine
PregnancyB - Usually safe but benefits must outweigh the risks.
PrecautionsBacterial or fungal overgrowth may result from prolonged antibiotic use; may increase hepatic enzymes and cholestatic jaundice; caution in patients with impaired hepatic function, prolonged QT intervals, or pneumonia; caution in patients who are hospitalized, geriatric, or debilitated

Drug NameClarithromycin (Biaxin)
DescriptionInhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest.
Adult Dose500 mg PO 1 h before procedure
Pediatric Dose15 mg/kg PO 1 h before procedure; not to exceed 500 mg/dose
ContraindicationsDocumented hypersensitivity; coadministration with pimozide
InteractionsToxicity increases with coadministration of fluconazole, astemizole, and pimozide; effects decrease and GI adverse effects may increase with coadministration of rifabutin or rifampin; may increase toxicity of anticoagulants, cyclosporine, tacrolimus, digoxin, omeprazole, carbamazepine, ergot alkaloids, triazolam, HMG CoA-reductase inhibitors; cardiac arrhythmias may occur with coadministration of cisapride; plasma levels of certain benzodiazepines may increase, prolonging CNS depression; arrhythmias and increases in QTc intervals occur with disopyramide; coadministration with omeprazole may increase plasma levels of both agents
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCoadministration with ranitidine or bismuth citrate not recommended with CrCl <25 mL/min; administer one half dose or increase dosing interval if CrCl <30 mL/min; diarrhea may be sign of pseudomembranous colitis; superinfections may occur with prolonged or repeated antibiotic therapies



Further Inpatient Care

  • Follow-up care is dictated by the type of cardiac defect and/or associated noncardiac manifestations. Patients with univentricular physiology typically require staged palliation, repeated hospitalization for preoperative evaluation, and perioperative care. Other inpatient care may be dictated by associated noncardiac lesions.

Further Outpatient Care

  • Patients with polysplenia syndrome often have univentricular physiology and/or very complex anatomy requiring staged palliative procedures and lifelong cardiac follow-up.
  • Patients with functional asplenia require careful evaluation of fever. They are at risk for overwhelming sepsis. Fevers without obvious cause should be evaluated with a blood culture, and admission for intravenous antibiotics, until the culture results are available, should be considered.

In/Out Patient Meds

  • Anticongestive therapy is required in most patients, along with anticoagulation and vasodilator therapy. No consensus exists on the most appropriate medical regimen for these patients, and the broad range of manifestations makes studies regarding the safety and efficacy of drug regimens difficult.
  • Many patients with palliated polysplenia syndrome develop arrhythmia, requiring medication. Consensus on the most appropriate antiarrhythmic medications or interventional therapy also is lacking.
  • Patients with functional asplenia require antibiotic prophylaxis. The usual regimen is amoxicillin once daily.

Complications

  • Complications from polysplenia syndrome can arise from the cardiac defects, the intestinal defects, or the immunodeficiency. The most common cardiac complications are congestive heart failure and arrhythmia. Careful prospective management of pulmonary blood flow, AV valve regurgitation, and cyanosis can help prevent the early onset of ventricular dysfunction and congestive heart failure; however, this complication is nearly universal in these patients. Arrhythmia can result from an absent or poorly functioning sinus node or from intra-atrial reentry around surgical scars. Patients with a history of pulmonary vein repair appear to be particularly prone to this complication. Antiarrhythmic therapy and pacemaker implantation often are required in these cases.
  • Gastrointestinal complications usually arise from malrotation with volvulus but can also result from annular pancreas, esophageal or intestinal atresia, and biliary tree abnormalities.
  • Complications arising from functional asplenia can include overwhelming sepsis, often leading to loss of extremities or death.

Prognosis

  • The prognosis for polysplenia syndrome is closely related to the cardiac manifestations. In a 26-year study period, the overall survival rate in the large series of 91 patients from Toronto was 31%; the 5-year survival rate was less than 40%. Risk factors for poor outcome included unobstructed pulmonary blood flow, obstructed pulmonary venous return, and major AV valve anomalies.

Patient Education

  • Patient education usually starts with educating parents on the care of infants with heart disease. The importance of routine follow-up, adherence to the medical regimen, and risk of infection should be stressed. In addition, early discussions about the relatively poor prognosis, potential need for orthotopic heart transplant, and need for multiple palliative procedures often help parents to cope with this chronic condition.



Medical/Legal Pitfalls

  • The most common medicolegal pitfall in this patient population seems to be failure to recognize sepsis in a patient with polysplenia who is functionally asplenic. Rapidly fatal infections are common in asplenic patients and often occur shortly after the onset of fever in an otherwise healthy appearing child. The lack of an ill appearance in these children should not be reassuring. All asplenic patients should be evaluated carefully, and inpatient observation with prophylactic antibiotics should be considered.

Special Concerns

  • Patients who survive to childbearing age are generally discouraged from carrying a pregnancy to term because the likelihood of carrying a pregnancy to term is low, and the maternal risk is high. However, patients with polysplenia have survived pregnancies and delivered term healthy babies without congenital heart disease.



  • Atkinson DE, Drant S. Diagnosis of heterotaxy syndrome by fetal echocardiography. Am J Cardiol. Nov 1 1998;82(9):1147-9, A10. [Medline].
  • Bartram U, Wirbelauer J, Speer CP. Heterotaxy syndrome -- asplenia and polysplenia as indicators of visceral malposition and complex congenital heart disease. Biol Neonate. 2005;88(4):278-90. [Medline].
  • Belmont JW, Mohapatra B, Towbin JA, Ware SM. Molecular genetics of heterotaxy syndromes. Curr Opin Cardiol. May 2004;19(3):216-20. [Medline][Full Text].
  • Berg C, Geipel A, Kamil D, et al. The syndrome of left isomerism: sonographic findings and outcome in prenatally diagnosed cases. J Ultrasound Med. Jul 2005;24(7):921-31. [Medline][Full Text].
  • Chen SJ, Li YW, Wang JK, et al. Usefulness of electron beam computed tomography in children with heterotaxy syndrome. Am J Cardiol. Jan 15 1998;81(2):188-94. [Medline].
  • Ditchfield MR, Hutson JM. Intestinal rotational abnormalities in polysplenia and asplenia syndromes. Pediatr Radiol. May 1998;28(5):303-6. [Medline].
  • Gayer G, Apter S, Jonas T, et al. Polysplenia syndrome detected in adulthood: report of eight cases and review of the literature. Abdom Imaging. Mar-Apr 1999;24(2):178-84. [Medline].
  • Gilljam T, McCrindle BW, Smallhorn JF, et al. Outcomes of left atrial isomerism over a 28-year period at a single institution. J Am Coll Cardiol. Sep 2000;36(3):908-16. [Medline].
  • Hofstaetter C, Plath H, Hansmann M. Prenatal diagnosis of abnormalities of the fetal venous system. Ultrasound Obstet Gynecol. Mar 2000;15(3):231-41. [Medline].
  • Ticho BS, Van Praagh R. Inherited structural heart diseases associated with arrhythmias: Defects in laterality. In: Berul CI, Towbin JA, eds. Molecular Genetics of Cardiac Electrophysiology. Boston, Mass:. Kluwer Academic Publishers;2000:317-328.
  • Uemura H, Ho SY, Devine WA, Anderson RH. Analysis of visceral heterotaxy according to splenic status, appendage morphology, or both. Am J Cardiol. Oct 15 1995;76(11):846-9. [Medline].
  • Uemura H, Ho SY, Anderson RH, Yagihara T. Ventricular morphology and coronary arterial anatomy in hearts with isometric atrial appendages. Ann Thorac Surg. May 1999;67(5):1403-11. [Medline].
  • Yoo SJ, Kim YM, Choe YH. Magnetic resonance imaging of complex congenital heart disease. Int J Card Imaging. Apr 1999;15(2):151-60. [Medline].
  • Zissin R, Rathaus V, Oscadchy A, et al. Intestinal malrotation as an incidental finding on CT in adults. Abdom Imaging. Nov-Dec 1999;24(6):550-5. [Medline].

Heterotaxy, Polysplenia excerpt

Article Last Updated: Apr 13, 2006